NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 1 pharmaceutical company such as UCB INC. It is marketed under 1 brand name, including ZILBRYSQ. Available in 3 different strengths, such as EQ 16.6MG BASE/0.416ML (EQ 16.6MG BASE/0.416ML), EQ 23MG BASE/0.574ML (EQ 23MG BASE/0.574ML), EQ 32.4MG BASE/0.81ML (EQ 32.4 BASE/0.81ML), and administered through 1 route including SOLUTION;SUBCUTANEOUS.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"118052","ingredient":"ZILUCOPLAN SODIUM","trade_name":"ZILBRYSQ","family_id":"bd65e5f595c74a339224","publication_number":"US10106579B2","cleaned_patent_number":"10106579","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-06-12","publication_date":"2018-10-23","legal_status":"Granted"} | US10106579B2 Molecular Formulation | 23 Oct, 2018 | Granted | 12 Jun, 2035 | |
| {"application_id":"118053","ingredient":"ZILUCOPLAN SODIUM","trade_name":"ZILBRYSQ","family_id":"bd65e5f595c74a339224","publication_number":"US10208089B2","cleaned_patent_number":"10208089","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-06-12","publication_date":"2019-02-19","legal_status":"Granted"} | US10208089B2 Molecular | 19 Feb, 2019 | Granted | 12 Jun, 2035 | |
| {"application_id":"118055","ingredient":"ZILUCOPLAN SODIUM","trade_name":"ZILBRYSQ","family_id":"bd65e5f595c74a339224","publication_number":"US10435438B2","cleaned_patent_number":"10435438","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-06-12","publication_date":"2019-10-08","legal_status":"Granted"} | US10435438B2 Molecular | 08 Oct, 2019 | Granted | 12 Jun, 2035 | |
| {"application_id":"118056","ingredient":"ZILUCOPLAN SODIUM","trade_name":"ZILBRYSQ","family_id":"bd65e5f595c74a339224","publication_number":"US10562934B2","cleaned_patent_number":"10562934","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-06-12","publication_date":"2020-02-18","legal_status":"Granted"} | US10562934B2 Molecular | 18 Feb, 2020 | Granted | 12 Jun, 2035 | |
| {"application_id":"117983","ingredient":"ZILUCOPLAN SODIUM","trade_name":"ZILBRYSQ","family_id":"d0c996ddb0814c9fb2bf","publication_number":"US10835574B2","cleaned_patent_number":"10835574","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-06-12","publication_date":"2020-11-17","legal_status":"Granted"} | US10835574B2 Formulation | 17 Nov, 2020 | Granted | 12 Jun, 2035 | |
| {"application_id":"117989","ingredient":"ZILUCOPLAN SODIUM","trade_name":"ZILBRYSQ","family_id":"bd65e5f595c74a339224","publication_number":"US11014965B2","cleaned_patent_number":"11014965","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-06-12","publication_date":"2021-05-25","legal_status":"Patented case"} | US11014965B2 Molecular | 25 May, 2021 | Patented case | 12 Jun, 2035 | |
| {"application_id":"118059","ingredient":"ZILUCOPLAN SODIUM","trade_name":"ZILBRYSQ","family_id":"bd65e5f595c74a339224","publication_number":"US11535650B1","cleaned_patent_number":"11535650","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-06-12","publication_date":"2022-12-27","legal_status":"Granted"} | US11535650B2 Formulation | 27 Dec, 2022 | Granted | 12 Jun, 2035 | |
| {"application_id":"117943","ingredient":"ZILUCOPLAN SODIUM","trade_name":"ZILBRYSQ","family_id":"d0c996ddb0814c9fb2bf","publication_number":"US11752190B2","cleaned_patent_number":"11752190","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-06-12","publication_date":"2023-09-12","legal_status":"Granted"} | US11752190B2 Formulation | 12 Sep, 2023 | Granted | 12 Jun, 2035 | |
| {"application_id":"118061","ingredient":"ZILUCOPLAN SODIUM","trade_name":"ZILBRYSQ","family_id":"bd65e5f595c74a339224","publication_number":"US11965040B2","cleaned_patent_number":"11965040","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-06-12","publication_date":"2024-04-23","legal_status":"Granted"} | US11965040B2 Formulation | 23 Apr, 2024 | Granted | 12 Jun, 2035 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Zilucoplan Sodium
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.